ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.14B |
| Gross Profit (TTM) | $706.66M |
| EBITDA | $98.39M |
| Operating Margin | 12.30% |
| Return on Equity | 35.70% |
| Return on Assets | 3.64% |
| Revenue/Share (TTM) | $6.69 |
| Book Value | $7.59 |
| Price-to-Book | 3.35 |
| Price-to-Sales (TTM) | 3.11 |
| EV/Revenue | 3.07 |
| EV/EBITDA | 35.53 |
| Quarterly Earnings Growth (YoY) | 13.30% |
| Quarterly Revenue Growth (YoY) | 16.40% |
| Shares Outstanding | $172.31M |
| Float | $128.35M |
| % Insiders | 0.33% |
| % Institutions | 99.78% |
Volatility is currently expanding
Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) stock is trading lower on Thursday after the company announced topline Phase 2 results from its RADIANT clinical trial program evaluating remlifanserin for Alzheimer's disease psychosis.
Acadia Pharmaceuticals (ACAD) reported phase 2/3 results for remlifanserin in Alzheimer's disease psychosis, with the high dose missing statistical significance but showing positive efficacy trends. Remlifanserin's safety profile was clean, but the effect size on the primary endpoint was low, raising concerns about clinical utility and replicability in phase 3. I am now even less optimistic about remlifanserin's phase 3 success, lowering my probability of success to 25% due to efficacy and trial design concerns.
Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 9% Thursday morning after the company reported mixed Phase 2 results for remlifanserin, its experimental treatment for Alzheimer's disease psychosis. The once-daily 60 mg dose eased hallucinations and delusions more than placebo on the trial's main measure, but the result fell just short of statistical significance at six weeks.
ACADIA Pharmaceuticals NASDAQ: ACAD reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer's disease psychosis, or ADP. The company said the 60 mg once-daily dose narrowly missed statistical significance on the primary endpoint but showed nominal statistical significance on a key secondary endpoint, while demonstrating a safety and tolerability profile comparable with placebo.
Acadia Pharmaceuticals said on Thursday its experimental drug for psychosis associated with Alzheimer's missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions in patients with the condition.
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACAD and any ticker you trade — then tracks every position and per-strategy win rate.
